title: PI3K pathway inhibition in GBM—is there a signal?
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York (D.N., I.K.M.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, New York (I.K.M.).
authors.forename: Donna
authors.initials: D
authors.lastname: Nichol
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York (D.N., I.K.M.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, New York (I.K.M.).
authors.forename: Ingo K
authors.initials: IK
authors.lastname: Mellinghoff
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003606:Dacarbazine / Q000031:analogs & derivatives*; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006067:Gonanes / Q000627:therapeutic use*; D006801:Humans; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D006067:Gonanes; D003606:Dacarbazine; D000068338:Everolimus